Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00919893
Recruitment Status : Completed
First Posted : June 12, 2009
Results First Posted : June 12, 2009
Last Update Posted : June 17, 2009
Sponsor:
Collaborators:
Strathmann AG&Co, Hamburg, Germany
Cernelle, Ängelholm, Sweden
Information provided by:
University of Giessen

Brief Summary:
In this placebo controlled study the safety and efficacy of Cernilton, a standardized pollen extract, in men with inflammatory chronic prostatitis-chronic pelvic pain syndrome was investigated. The purpose of this study is to determine whether Cernilton is safe and effective in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome.

Condition or disease Intervention/treatment Phase
Chronic Prostatitis Chronic Pelvic Pain Syndrome Drug: Cernilton Drug: Placebo Phase 3

Detailed Description:
We conducted a multicenter, randomized, double-blind, placebo-controlled trial to assess safety and efficacy of Cernilton, a standardized pollen extract, in men with inflammatory CP-CPPS (National Institutes of Health (NIH) type IIIA). Participants were randomized to Cernilton or placebo for 12 weeks and were evaluated using the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) individual domains and total score, the number of leukocytes in post prostatic massage urine, the International Prostate Symptom Score (IPSS) and the sexuality domain of a life satisfaction questionnaire at baseline and after 6 and 12 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 139 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase 3 Study of a Standardized Pollen Extract Preparation (Cernilton) in Patients With Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome
Study Start Date : December 1999
Actual Primary Completion Date : January 2004
Actual Study Completion Date : January 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pelvic Pain

Arm Intervention/treatment
Active Comparator: Cernilton
Men with inflammatory chronic prostatitis-chronic pelvic pain syndrome (CP-CPPS)
Drug: Cernilton
Oral Cernilton, 2 capsules every 8 hours with the active substance consisting of 23 mg Extractum Pollens siccatum, 4 mg L-glutamate and 0.23 mg Stigmasterol per capsule for 12 weeks.

Placebo Comparator: Placebo
Men with inflammatory chronic prostatitis-chronic pelvic pain syndrome (CP-CPPS)
Drug: Placebo
Oral placebo, 2 capsules every 8 hours with identical capsulation and weight only containing the inactive substances in proportional doses as compared with Cernilton for 12 weeks.




Primary Outcome Measures :
  1. Symptomatic Improvement in the Pain Domain of National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) [ Time Frame: 0, 6, 12 weeks ]
    Decrease in NIH-CPSI pain score. Best value: 0. Worst value: 21.


Secondary Outcome Measures :
  1. Secondary Outcomes Were Symptomatic Improvement of the NIH-CPSI Total Score, the Micturition and Life Quality Domains of the NIH-CPSI Questionnaire, Decrease in the Number of Leukocytes in Urine. [ Time Frame: 0, 6, 12 weeks ]
    Decrease of score points. Decrease of leucocytes in urine.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • men between 18 and 65 years
  • symptoms of pelvic pain for at least 3 months during the 6 months before study entry
  • a score in the pain domain of the German validated version of the NIH chronic prostatitis symptom index (NIH-CPSI) of 7 or higher
  • leukocytes of 10 or more in post prostate massage urine

Exclusion Criteria:

  • urinary tract infection
  • acute bacterial or chronic bacterial prostatitis
  • history of urethritis with discharge 4 weeks prior to study entry
  • a history of epididymitis or sexually transmitted disease
  • residual urine volume of more than 50 mL due to bladder outlet obstruction
  • indication for or history of prostate surgery including prostate biopsy
  • treatment with phytotherapeutic agents
  • alpha-blocker agents or antimicrobial substances with prostatic penetration 4 weeks prior to study entry
  • treatment with agents influencing intraprostatic hormone metabolism 6 months prior to study entry

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00919893


Locations
Layout table for location information
Germany
Justus-Liebig-University
Giessen, Germany, D-35392
Sponsors and Collaborators
University of Giessen
Strathmann AG&Co, Hamburg, Germany
Cernelle, Ängelholm, Sweden
Investigators
Layout table for investigator information
Principal Investigator: Wolfgang Weidner, Prof. Dr. Clinic for Urology and Pediatric Urology, Justus-Liebig-University Giessen, Germany
Publications:
Layout table for additonal information
Responsible Party: Prof. Dr. Wolfgang Weidner, Clinic for Urology and Pediatric Urology, JL-University, Giessen, Germany
ClinicalTrials.gov Identifier: NCT00919893    
Other Study ID Numbers: 4015497
First Posted: June 12, 2009    Key Record Dates
Results First Posted: June 12, 2009
Last Update Posted: June 17, 2009
Last Verified: June 2009
Keywords provided by University of Giessen:
chronic prostatitis symptom index
male
inflammatory
CP-CPPS
Cernilton
pelvic pain
symptoms
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatitis
Syndrome
Pelvic Pain
Chronic Disease
Somatoform Disorders
Disease
Pathologic Processes
Mental Disorders
Pain
Neurologic Manifestations
Prostatic Diseases
Disease Attributes